EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Protein–Protein interactive networks identified in bronchoalveolar lavage of severe compared to nonsevere asthma

Annette T Hastie iD, Andrew C Bishop, Mohammad S Khan, Eugene R Bleecker, Mario Castro, Loren C Denlinger, Serpil C Erzurum, John V Fahy, Elliot Israel, Bruce D Levy, David T Mauger, Deborah A Meyers and 5 more

Clinical & Experimental Allergy · 2024

DOI: 10.1111/cea.14447 ↗

At a glance

Journal article in Clinical & Experimental Allergy, 2024. Written by Annette T Hastie and 16 co-authors. Institution: Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Major MEDLINE topics: Vascular Endothelial Growth Factor A, Asthma. Cited 13 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NHLBI NIH HHS, AstraZeneca, National Heart, Lung, and Blood Institute.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Previous bronchoalveolar lavage fluid (BALF) proteomic analysis has evaluated limited numbers of subjects for only a few proteins of interest, which may differ between asthma and normal controls. Our objective was to examine a more comprehensive inflammatory biomarker panel in quantitative proteomic analysis for a large asthma cohort to identify molecular phenotypes distinguishing severe from nonsevere asthma.

Methods

Bronchoalveolar lavage fluid from 48 severe and 77 nonsevere adult asthma subjects were assessed for 75 inflammatory proteins, normalized to BALF total protein concentration. Validation of BALF differences was sought through equivalent protein analysis of autologous sputum. Subjects' data, stratified by asthma severity, were analysed by standard statistical tests, principal component analysis and 5 machine learning algorithms.

Results

The severe group had lower lung function and greater health care utilization. Significantly increased BALF proteins for severe asthma compared to nonsevere asthma were fibroblast growth factor 2 (FGF2), TGFα, IL1Ra, IL2, IL4, CCL8, CCL13 and CXCL7 and significantly decreased were platelet‐derived growth factor a‐a dimer (PDGFaa), vascular endothelial growth factor (VEGF), interleukin 5 (IL5), CCL17, CCL22, CXCL9 and CXCL10. Four protein differences were replicated in sputum. FGF2, PDGFaa and CXCL7 were independently identified by 5 machine learning algorithms as the most important variables for discriminating severe and nonsevere asthma. Increased and decreased proteins identified for the severe cluster showed significant protein–protein interactions for chemokine and cytokine signalling, growth factor activity, and eosinophil and neutrophil chemotaxis differing between subjects with severe and nonsevere asthma.

Conclusion

These inflammatory protein results confirm altered airway remodelling and cytokine/chemokine activity recruiting leukocytes into the airways of severe compared to nonsevere asthma as important processes even in stable status.

Subjects

MeSH terms (MEDLINE)

Vascular Endothelial Growth Factor AAsthmaAdultHumansProteomicsFibroblast Growth Factor 2CytokinesBronchoalveolar LavageChemokinesBronchoalveolar Lavage Fluid

Author keywords

bronchoalveolar lavage fluidchemokinescytokinesgrowth factorsmachine learningsevere asthma

Substances

Vascular Endothelial Growth Factor AFibroblast Growth Factor 2CytokinesChemokines

Authors and institutions

  • Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
  • Department of Pulmonary, Critical Care and Sleep Medicine, Kansas University Medical Center, Kansas City, Kansas, USA.
  • Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pulmonary and Critical Care Medicine, University of California-San Francisco, San Francisco, California, USA.

ORCID profiles: Annette T Hastie

Funding

  • NHLBI NIH HHS
  • AstraZeneca
  • National Heart, Lung, and Blood Institute
  • Genentech
  • Boehringer Ingelheim
  • MedImmune
  • GlaxoSmithKline
  • Regeneron Pharmaceuticals

Cite

APA

Hastie, A. T., Bishop, A. C., Khan, M. S., Bleecker, E. R., Castro, M., Denlinger, L. C., Erzurum, S. C., Fahy, J. V., Israel, E., Levy, B. D., Mauger, D. T., Meyers, D. A., Moore, W. C., Ortega, V. E., Peters, S. P., Wenzel, S. E., & Steele, C. H. (2024). Protein–Protein interactive networks identified in bronchoalveolar lavage of severe compared to nonsevere asthma. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14447

Vancouver

Hastie AT, Bishop AC, Khan MS, Bleecker ER, Castro M, Denlinger LC, et al. Protein–Protein interactive networks identified in bronchoalveolar lavage of severe compared to nonsevere asthma. Clinical & Experimental Allergy. 2024. doi:10.1111/cea.14447

BibTeX
@article{Hastie2024,
  author = {Hastie, Annette T and Bishop, Andrew C and Khan, Mohammad S and Bleecker, Eugene R and Castro, Mario and Denlinger, Loren C and Erzurum, Serpil C and Fahy, John V and Israel, Elliot and Levy, Bruce D and Mauger, David T and Meyers, Deborah A and Moore, Wendy C and Ortega, Victor E and Peters, Stephen P and Wenzel, Sally E and Steele, Chad H},
  title = {Protein–Protein interactive networks identified in bronchoalveolar lavage of severe compared to nonsevere asthma},
  journal = {Clinical & Experimental Allergy},
  year = {2024},
  doi = {10.1111/cea.14447}
}
Start for free →